Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Hologic reported its fiscal Q1 2024 results, demonstrating strong financial performance with total revenue reaching $1.01 billion, above the high end of the company’s guidance.</li><li>In spite of four fewer selling days than in Q1 2023, the firm achieved total organic revenue growth, excluding COVID-19, of 5.2%.</li><li>When adjusted for the fewer selling days, estimated total company organic revenue growth excluding COVID-19 was in the high single digits.</li></ul>

Hologic reported its fiscal Q1 2024 results, demonstrating strong financial performance with total revenue reaching $1.01 billion, above the high end of the company’s guidance.In spite of four fewer selling days than in Q1 2023, the firm achieved total organic revenue growth, excluding COVID-19, of 5.2%.When adjusted for the fewer selling days, estimated total company organic revenue growth excluding COVID-19 was in the high single digits.

Hologic Inc: Fortifying Market Position Through Innovation & Strategic Acquisitions! - Major Drivers

<ul><li>Hologic, Inc. managed to exceed analyst expectations in terms of revenue as well as earnings, concluding Q4 with total revenue at $945.3 million and non-GAAP earnings per share at $0.89.</li><li>The Q4 results highlighted a 16.7% total organic revenue growth, excluding COVID-19, with double-digit growth in all divisions.</li><li>Notably, the company deployed substantial capital for share repurchases in Q4 2023 and Q1 2024, with an additional $500 million accelerated share repurchase program announced.</li></ul>

Hologic, Inc. managed to exceed analyst expectations in terms of revenue as well as earnings, concluding Q4 with total revenue at $945.3 million and non-GAAP earnings per share at $0.89.The Q4 results highlighted a 16.7% total organic revenue growth, excluding COVID-19, with double-digit growth in all divisions.Notably, the company deployed substantial capital for share repurchases in Q4 2023 and Q1 2024, with an additional $500 million accelerated share repurchase program announced.

Hologic Inc.: Anticipating Continued Growth Across Divisions - What's the Outlook for 2024? - Major Drivers

<ul><li>Hologic, Inc. exceeded analyst expectations in terms of revenue as well as earnings.</li><li>Non-GAAP earnings per share were $0.93 and the total revenue was $984 million.</li><li>In Mammography, Hologic delivered more gantries in Q3 than in Q1 and significantly fewer than in Q2.</li></ul>

Hologic, Inc. exceeded analyst expectations in terms of revenue as well as earnings.Non-GAAP earnings per share were $0.93 and the total revenue was $984 million.In Mammography, Hologic delivered more gantries in Q3 than in Q1 and significantly fewer than in Q2.

Hologic Inc.: Decoding the Reasons Behind the Double-Digit Molecular Growth! - Major Drivers

<ul><li>Hologic managed to exceed the revenue expectations as well as the earnings expectations of Wall Street.</li><li>The company's financial results surpassed expectations, driven by robust organic revenue growth in key divisions like Diagnostics, Surgical, and Breast Health excluding COVID-19, driven by new products, market expansion and customer loyalty.</li><li>Hologic's COVID-19 assay revenue was $233 million, down 47% sequentially, reflecting lower testing demand and increased competition.</li></ul>

Hologic managed to exceed the revenue expectations as well as the earnings expectations of Wall Street.The company's financial results surpassed expectations, driven by robust organic revenue growth in key divisions like Diagnostics, Surgical, and Breast Health excluding COVID-19, driven by new products, market expansion and customer loyalty.Hologic's COVID-19 assay revenue was $233 million, down 47% sequentially, reflecting lower testing demand and increased competition.

Hologic Inc.: 3 Key Drivers & Strategic Priorities Driving Growth – Financial Forecasts

Global Healthcare Analyst

Tina Banerjee

<ul>
<li>With multiple mutations, Omicron may require modifications in the existing vaccines. With fast mover advantage and superior efficacy, <a href="https://www.smartkarma.com/entities/moderna-inc" target="_blank" data-smartkarma-citation="entities:28744:1" rel="noopener">Moderna Inc (MRNA US)</a> seems to be a clear winner of the situation.</li>
<li>Moderna’s current expectation to deliver 2–3 billion doses in 2022 is likely to be revised upwards with the fast spread of Omicron vaccine and full approval of booster doses.</li>
<li>Moderna shares have reasonable valuation compared to its peers. Higher visibility into 2022 and beyond will lead to re-rating opportunity.</li>
</ul>


With multiple mutations, Omicron may require modifications in the existing vaccines. With fast mover advantage and superior efficacy, Moderna Inc (MRNA US) seems to be a clear winner of the situation.
Moderna’s current expectation to deliver 2–3 billion doses in 2022 is likely to be revised upwards with the fast spread of Omicron vaccine and full approval of booster doses.
Moderna shares have reasonable valuation compared to its peers. Higher visibility into 2022 and beyond will lead to re-rating opportunity.


Moderna (MRNA US): To Cash in on Omicron Fear

United States

Hologic, Inc. is a developer, manufacturer and supplier of premium diagnostic products, medical imaging systems, and surgical products. The Company's core business units focus on diagnostics, breast health, GYN surgical, and skeletal health.

Hologic Inc (HOLX US)

Hologic Inc: Fortifying Market Position Through Innovation & Strategic Acquisitions! - Major Drivers

Hologic reported its fiscal Q1 2024 results, demonstrating strong financial performance with total revenue reaching $1.01 billion, above the high...

Baptista Research

Hologic Inc.: Anticipating Continued Growth Across Divisions - What's the Outlook for 2024? - Major Drivers

Hologic, Inc. managed to exceed analyst expectations in terms of revenue as well as earnings, concluding Q4 with total revenue at $945.3 million...

Baptista Research

Hologic Inc.: Decoding the Reasons Behind the Double-Digit Molecular Growth! - Major Drivers

Hologic, Inc. exceeded analyst expectations in terms of revenue as well as earnings. Non-GAAP earnings per share were $0.93 and the total revenue...

Baptista Research

Hologic Inc.: 3 Key Drivers & Strategic Priorities Driving Growth – Financial Forecasts

Hologic managed to exceed the revenue expectations as well as the earnings expectations of Wall Street. The company's financial results surpassed...

Baptista Research

Moderna (MRNA US): To Cash in on Omicron Fear

Moderna is set to fly high on the continuous increasing demand for its Covid vaccine and rich pipeline beyond Covid. Emerging Omicron variant is...

Tina Banerjee